Afelimomab

Identification

Name
Afelimomab
Accession Number
DB04956
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

Protein structure
Db04956
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Fab 2
  • MAK 195F
International/Other Brands
Segard
Categories
UNII
6SC756X51V
CAS number
156227-98-4

Pharmacology

Indication

Investigated for use/treatment in sepsis and septicemia.

Structured Indications
Not Available
Pharmacodynamics

Afelimomab is the F(ab')2 fragment of a murine anti-TNF-alpha antibody, and has been evaluated in clinical trials in septic patients. The results suggest that the drug is well tolerated, and may be of benefit in certain groups of patients with sepsis. Afelimomab is safe, biologically active, and well tolerated in patients with severe sepsis, reduces 28-day all-cause mortality, and attenuates the severity of organ dysfunction in patients with elevated interleukin-6 levels.

Mechanism of action
TargetActionsOrganism
UTumor necrosis factorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

44.7 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbataceptThe risk or severity of infection can be increased when Afelimomab is combined with Abatacept.Approved
AnakinraThe risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Afelimomab.Investigational
CanakinumabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Canakinumab.Approved, Investigational
Certolizumab pegolAfelimomab may increase the immunosuppressive activities of Certolizumab pegol.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Afelimomab.Approved
FingolimodAfelimomab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Afelimomab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Afelimomab.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Afelimomab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Afelimomab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Afelimomab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Afelimomab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Afelimomab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Afelimomab.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Afelimomab.Approved
RilonaceptThe risk or severity of adverse effects can be increased when Afelimomab is combined with Rilonacept.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Afelimomab.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Afelimomab.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Afelimomab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Afelimomab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Afelimomab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Afelimomab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Afelimomab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Afelimomab.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Afelimomab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Afelimomab.Investigational
TocilizumabTocilizumab may increase the immunosuppressive activities of Afelimomab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Afelimomab is combined with Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Afelimomab.Approved, Investigational
VedolizumabThe risk or severity of infection can be increased when Afelimomab is combined with Vedolizumab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Afelimomab.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Afelimomab.Approved
Food Interactions
Not Available

References

General References
  1. Vincent JL: Afelimomab. Int J Clin Pract. 2000 Apr;54(3):190-3. [PubMed:10829362]
  2. Gallagher J, Fisher C, Sherman B, Munger M, Meyers B, Ellison T, Fischkoff S, Barchuk WT, Teoh L, Velagapudi R: A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med. 2001 Jul;27(7):1169-78. [PubMed:11534565]
External Links
PubChem Substance
347909858
Wikipedia
Afelimomab
ATC Codes
L04AB03 — Afelimomab

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Vincent JL: Afelimomab. Int J Clin Pract. 2000 Apr;54(3):190-3. [PubMed:10829362]

Drug created on October 21, 2007 16:23 / Updated on November 06, 2017 06:45